The Life Sciences IPOs + Capital Markets team advised Goldman Sachs & Co. LLC and the other underwriters of Harmony Biosciences Holdings, Inc.’s (Nasdaq: HRMY) upsized initial public offering of 6,151,162 shares of common stock, including 802,325 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at the public offering price of $24.00 per share. The gross proceeds of the offering were $147.6 million before deducting underwriting commissions and estimated offering expenses.
Harmony is a commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
The Goodwin team was led by Robert Puopolo, and Peter Rodas, and included Elizabeth Mulkey, Nikhil Sethi, Duncan Greenhalgh, Olivia Uitto, Sarah Bock, Jennifer Fay and Janet Andolina.
For more details, read the press release and articles in Endpoints, S&P Global, and Philadelphia Business Journal.